Testing a new Alzheimer's drug with Leqembi
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This study tests a new combination treatment (X/T plus X-EC) for people with Alzheimer's who are already taking Leqembi (lecanemab). It aims to see if the new drug is safe and well-tolerated.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 to 85 years old.
- You have a diagnosis of Alzheimer's disease and are currently taking Leqembi (lecanemab) with at least 14 infusions completed.
- You have a caregiver or study partner who can come to all visits and report on your symptoms.
- You have a stable living situation (home, nursing home, assisted living, or memory care) for at least 6 weeks.
- You are generally healthy with no serious heart, liver, kidney, or bladder problems, and no recent stroke or bleeding in the brain.
- You are willing to stop certain other medications and follow study rules.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects real-world safety information from people taking the Alzheimer's drug LEQEMBI (also known as lecanemab). It helps doctors understand how well the medicine works outside of clinical trials and what side effects may occur.
This study follows people with Alzheimer's who are already taking Leqembi (lecanemab) after being in the JOY-ALZ study. It collects medical information to check how the treatment works in real-world use.
This study collects information from people in Canada who have Alzheimer's disease and are prescribed the drug lecanemab (LEQEMBI). It helps doctors learn more about the drug's safety and effects in real-world use.
This study tracks the real-world experience of people with early Alzheimer's disease who are already taking lecanemab. It aims to better understand how the medication works and its safety in everyday medical practice.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
Hear when a new Alzheimer’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.